DRUG · Unmapped registry intervention
Allogeneic NK Cells
Find medicine records ·
Find other trials using this name
Clinical trial
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
NCT06991114
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Refractory Rheumatoid Arthritis (RA)unresolved
Systemic Sclerosis (SSc)unresolved
Rheumatoid Arthritis (RAunresolved
Myositisunresolved
Sclerodermaverified · MONDO: scleroderma
Sjogren Syndromeverified · MONDO: Sjogren syndrome
Sjogrens Diseaseunresolved
Interventions
Sponsors & collaborators
Artiva Biotherapeutics, Inc.lead sponsor
Mapped research locations
CharlotteNorth Carolina, United States2BucharestRomania2São PauloSão Paulo, Brazil2Los AngelesCalifornia, United States1MiamiFlorida, United States1PhoenixArizona, United States1CharlestonSouth Carolina, United States1TucsonArizona, United States1ToulouseFrance1SevilleSpain1MarseilleFrance1MontpellierFrance1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06991114 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.